Epigenetic reprograming of immune cells through selective inhibition of HDAC6 reduces suppressive phenotypes and augments anti-tumor properties of T-cells

被引：1
作者：
Sodre, Andressa L.
Woods, David M.
Sarnaik, Amod
Betts, Brian C.
Quayle, Steven
Jones, Simon
Weber, Jeffrey
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-638
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
638
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+T cells
    Gomez Aleza, Clara
    Nguyen, Bastien
    Yoldi, Guillermo
    Ciscar, Marina
    Barranco, Alexandra
    Hernandez Jimenez, Enrique
    Maetens, Marion
    Salgado, Roberto
    Zafeiroglou, Maria
    Pellegrini, Pasquale
    Venet, David
    Garaud, Soizic
    Trinidad, Eva M.
    Benitez, Sandra
    Munoz, Purificacion
    Walzer, Thierry
    Planelles, Lourdes
    Penninger, Josef
    Azim, Hatem A., Jr.
    Loi, Sherene
    Piccart, Martine
    Sotiriou, Christos
    Gonzalez Suarez, Eva
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 239 - 239
  • [42] TRAF6 signaling pathway in T cells regulates anti-tumor immunity through the activation of tumor specific Th9 cells and CTLs
    Dewayani, Astri
    Kamiyama, Naganori
    Sachi, Nozomi
    Ozaka, Sotaro
    Saechue, Benjawan
    Ariki, Shimpei
    Goto, Mizuki
    Chalalai, Thanyakorn
    Soga, Yasuhiro
    Fukuda, Chiaki
    Kagoshima, Yomei
    Maekawa, Yoichi
    Kobayashi, Takashi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 613 : 26 - 33
  • [43] Author Correction: Selective HDAC6 inhibitors improve anti-PD-1 immune checkpoint blockade therapy by decreasing the anti-inflammatory phenotype of macrophages and down-regulation of immunosuppressive proteins in tumor cells
    Tessa Knox
    Eva Sahakian
    Debarati Banik
    Melissa Hadley
    Erica Palmer
    Satish Noonepalle
    Jennifer Kim
    John Powers
    Maria Gracia-Hernandez
    Vasco Oliveira
    Fengdong Cheng
    Jie Chen
    Cyril Barinka
    Javier Pinilla-Ibarz
    Norman H. Lee
    Alan Kozikowski
    Alejandro Villagra
    Scientific Reports, 9
  • [44] Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System
    Avanzi, Mauro P.
    Yeku, Oladapo
    Li, Xinghuo
    Wijewarnasuriya, Dinali P.
    van Leeuwen, Dayenne G.
    Cheung, Kenneth
    Park, Hyebin
    Purdon, Terence J.
    Daniyan, Anthony F.
    Spitzer, Matthew H.
    Brentjens, Renier J.
    CELL REPORTS, 2018, 23 (07): : 2130 - 2141
  • [45] Blockage of Core Fucosylation Reduces Cell-Surface Expression of PD-1 and Promotes Anti-tumor Immune Responses of T Cells
    Okada, Masahiro
    Chikuma, Shunsuke
    Kondo, Taisuke
    Hibino, Sana
    Machiyama, Hiroaki
    Yokosuka, Tadashi
    Nakano, Miyako
    Yoshimura, Akihiko
    CELL REPORTS, 2017, 20 (05): : 1017 - 1028
  • [46] REGULATION OF THE IMMUNE-RESPONSE TO TUMOR-ANTIGENS .10. ACTIVATION OF 3RD-ORDER SUPPRESSOR T-CELLS THAT ABROGATE ANTI-TUMOR IMMUNE-RESPONSES
    SCHATTEN, S
    DREBIN, JA
    PERRY, LL
    CHUNG, W
    GREENE, MI
    JOURNAL OF IMMUNOLOGY, 1984, 133 (02) : 1064 - 1069
  • [47] Selective inhibition of inducible nitric oxide synthase enhances anti-tumor immune responses in rats immunized with IFN-γ:: secreting glioma cells
    Badn, W
    Hegardt, P
    Larsson, M
    Esbjornsson, M
    Salford, LG
    Visse, E
    Siesjo, P
    NITRIC OXIDE-BIOLOGY AND CHEMISTRY, 2004, 11 (01): : 104 - 104
  • [48] Ly6E on tumor cells impairs anti-tumor T-cell responses: a novel mechanism of tumor-induced immune exclusion
    Lan, Hailin
    Chen, Yiting
    Yue, Wu
    Li, Lijun
    Zhang, Renlu
    Chen, Yunhan
    Zhu, Yanyang
    Zhang, Qiuyu
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 74 (01)
  • [49] MPT0G413, A Novel HDAC6-Selective Inhibitor, and Bortezomib Synergistically Exert Anti-tumor Activity in Multiple Myeloma Cells
    Huang, Fang-, I
    Wu, Yi-Wen
    Sung, Ting-Yi
    Liou, Jing-Ping
    Lin, Mei-Hsiang
    Pan, Shiow-Lin
    Yang, Chia-Ron
    FRONTIERS IN ONCOLOGY, 2019, 9
  • [50] PD-L1 Checkpoint Blockade Augments Anti-Tumor Immune Response of GD2 or HER2-Bsab Ex Vivo Armed T-Cells (EVAT) Therapy in Osteosarcoma
    Park, Jeong A.
    Guo, Hong Fen
    Xu, Hong
    Cheung, Nai-Kong V.
    BLOOD, 2019, 134
12345